BioNTech (NASDAQ:BNTX) Receives Buy Rating from Canaccord Genuity Group

BioNTech (NASDAQ:BNTXGet Rating)‘s stock had its “buy” rating reissued by research analysts at Canaccord Genuity Group in a research note issued to investors on Wednesday, Benzinga reports. They presently have a $192.00 price target on the stock. Canaccord Genuity Group’s price target would suggest a potential upside of 19.23% from the stock’s current price.

Several other equities analysts also recently weighed in on BNTX. Morgan Stanley decreased their price target on shares of BioNTech from $217.00 to $197.00 and set an “equal weight” rating on the stock in a research note on Tuesday, April 12th. UBS Group set a $168.00 target price on shares of BioNTech in a research note on Thursday, June 30th. Berenberg Bank reaffirmed a “buy” rating and set a $350.00 target price on shares of BioNTech in a research note on Monday, April 11th. Jefferies Financial Group set a $230.00 target price on shares of BioNTech in a research note on Monday, May 9th. Finally, The Goldman Sachs Group set a $209.00 price target on shares of BioNTech in a research note on Thursday, June 30th. Seven research analysts have rated the stock with a hold rating and six have assigned a buy rating to the company. According to data from MarketBeat.com, BioNTech presently has a consensus rating of “Hold” and an average target price of $246.86.

NASDAQ:BNTX opened at $161.03 on Wednesday. The company’s 50-day moving average price is $148.52 and its 200-day moving average price is $167.34. The company has a current ratio of 5.05, a quick ratio of 4.93 and a debt-to-equity ratio of 0.01. The company has a market cap of $39.13 billion, a P/E ratio of 2.80 and a beta of -0.09. BioNTech has a twelve month low of $117.08 and a twelve month high of $464.00.

BioNTech (NASDAQ:BNTXGet Rating) last posted its quarterly earnings results on Monday, May 9th. The company reported $15.98 earnings per share for the quarter, topping the consensus estimate of $9.14 by $6.84. The firm had revenue of $6.37 billion for the quarter, compared to the consensus estimate of $4.50 billion. BioNTech had a net margin of 55.13% and a return on equity of 122.24%. The company’s revenue for the quarter was up 211.2% on a year-over-year basis. During the same period last year, the firm posted $5.29 earnings per share. On average, analysts expect that BioNTech will post 34.81 earnings per share for the current year.

Large investors have recently bought and sold shares of the company. KRS Capital Management LLC acquired a new position in shares of BioNTech during the 4th quarter worth $25,000. Koshinski Asset Management Inc. acquired a new position in shares of BioNTech during the 1st quarter worth $26,000. Covestor Ltd acquired a new position in shares of BioNTech during the 4th quarter worth $47,000. Loring Wolcott & Coolidge Fiduciary Advisors LLP MA grew its stake in shares of BioNTech by 66.7% during the 1st quarter. Loring Wolcott & Coolidge Fiduciary Advisors LLP MA now owns 250 shares of the company’s stock worth $43,000 after purchasing an additional 100 shares during the period. Finally, DeDora Capital Inc. acquired a new position in shares of BioNTech during the 1st quarter worth $51,000. 14.42% of the stock is currently owned by institutional investors and hedge funds.

About BioNTech (Get Rating)

BioNTech SE, a biotechnology company, develops and commercializes immunotherapies for cancer and other infectious diseases. The company is developing FixVac product candidates, including BNT111, which is in Phase II clinical trial for advance melanoma; BNT112 that is in Phase I/IIa clinical trial for prostate cancer; BNT113, which is in Phase II clinical trial to treat HPV+ head and neck cancers; BNT114 that is in Phase I clinical trial for triple negative breast cancer; BNT115, which is in Phase I clinical trial in ovarian cancer; and BNT116, a preclinical stage product for non-small cell lung cancer.

Read More

Analyst Recommendations for BioNTech (NASDAQ:BNTX)

Receive News & Ratings for BioNTech Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for BioNTech and related companies with MarketBeat.com's FREE daily email newsletter.